Journal
ACTA BIOMATERIALIA
Volume 10, Issue 2, Pages 858-867Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.actbio.2013.11.003
Keywords
Glioma; Dual drug delivery system; Tumor microenvironment; Evaluation model
Funding
- National Basic Research Program of China (973 Program) [2013CB932502]
- National Science and Technology Major Project [2012ZX09304004]
- National Natural Science Foundation of China [81001404]
Ask authors/readers for more resources
A dual targeting delivery system was developed to completely conquer the two barriers that glioma treatment faces: the blood-brain barrier (BBB) and the brain-glioma barrier. Recently, a system comprising AS1411 aptamer (for glioma targeting) and TGN peptide (for BBB targeting) modified nanoparticles (AsTNPs) was developed, which can effectively target brain glioma and improve the survival of glioma-bearing mice. However, the in vitro models currently used are far too different from the in vivo tumor microenvironment that the glioma targeting delivery system actually faces. In this study, the pharmacology mechanisms of AsTNPs were explored in several models that imitated the tumor microenvironment. AsTNPs can be selectively taken up by endothelial and glioma cells, effectively penetrating the BBB and brain-glioma barriers to reach glioma cells and display their anti-glioma effect. The cell monolayers, tumor spheroids and coculture systems were more suitable in vitro models for the pharmacology evaluation of targeted drug delivery systems. (C) 2013 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available